Indobufen

Summary

Indobufen (CHEMBL1765292) is a phase-3 clinical-stage small molecule (ATC B01AC10); indicated across 2 conditions including thrombotic disease and atrial fibrillation.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: B01AC10
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 295.3 Da · C18H17NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1765292
Name	Indobufen
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	107641
ATC	B01AC10
Molecular formula	C18H17NO3
Molecular weight	295.3
InChIKey	AYDXAULLCROVIT-UHFFFAOYSA-N

SMILES: CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O

IUPAC name: 2-[4-(3-oxo-1H-isoindol-2-yl)phenyl]butanoic acid

Also known as: Ibustrin, Indobufen, Indobufene, K-2930, K-3920, SID170466270, INDOBUFEN, indobufen, IndobufenÊ, IndobufenÂ

Patent coverage: 682 distinct patent families (2,314 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,277 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.1	AC50	800	nM	CHEMBL_ACT_25174854
HTR1A	5.72	AC50	1900	nM	CHEMBL_ACT_25216339
ADRA1A	5.28	AC50	5300	nM	CHEMBL_ACT_25218409

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	HP:0004419
atrial fibrillation	3	MONDO:0004981	EFO:0000275

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE4	3
Not specified	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06451198	PHASE4	RECRUITING	IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
NCT03871517	PHASE4	COMPLETED	INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
NCT04129008	PHASE4	UNKNOWN	GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy
NCT00244426	PHASE3	COMPLETED	S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
NCT01232023	PHASE1	UNKNOWN	Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent
NCT07089862	Not specified	RECRUITING	INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
NCT04308551	Not specified	WITHDRAWN	Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).